Department of Immunology, Royal London Hospital, Barts Health NHS Trust, London, UK.
National Guideline Centre, Royal College of Physicians, London, UK.
Clin Exp Immunol. 2022 Oct 21;210(1):1-13. doi: 10.1093/cei/uxac070.
Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.
目前，英国尚没有指南支持在原发性和继发性免疫缺陷疾病中使用免疫球蛋白替代疗法（IgRT）。英国原发性免疫缺陷网络（UK-PIN）和英国免疫学会（BSI）联手解决这一需求。鉴于证据不足，采用了改良德尔菲法，涵盖了 IgRT 起始、监测、停止以及家庭治疗方案的陈述。一组六名顾问免疫学家和三名护士专家制定了这些陈述，对回复和反馈进行了审查，并就最终建议达成一致。本指南包括 22 条 IgRT 起始的陈述、22 条 IgRT 监测的陈述、11 条家庭治疗的陈述和 19 条 IgRT 停止的陈述。还提出了进一步的研究领域，以改善未来的护理服务。
